GSK plc (GSK) Stock AnalysisGSKStock AnalysisGSK plc

GSK plc is a United Kingdom-based biopharma company. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its segments include Commercial Operations and Research and Development. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) to antibiotics. It also owns ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody and HS235, a potential molecule for the treatment of pulmonary hypertension (PH). Its oncology portfolio also includes Zidesamtinib (NVL-520), neladalkib (NVL-655), and NVL-330. Its products include Anoro Ellipta, Apretude, Arexvy, Bexsero, Blenrep, Blujepa, Boostrix, Cervarix, Dovato, Efimosfermin, among others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

GSK is currently trading at $50.82, and while it has shown a strong 1-year change of +30.44%, the RSI is at 43.19, indicating it is nearing oversold territory. The forward P/E ratio of 20.53 suggests that the stock may be overvalued relative to its earnings growth potential, especially given the projected 2% compound annual earnings growth, which is the weakest in the European pharmaceutical sector. The main risk is the ongoing litigation with AnaptysBio, which could negatively impact stock performance depending on the outcome expected in early 2027.

4 analysts cover GSK: 1 rate it Buy, 3 Hold and 0 Sell. The average price target is 38.72.